

Preliminary Tests Show Anti-STI Vaginal Ring is Effective in Preventing Genital Herpes Infection

A new vaginal ring has been developed that can deliver hydrophilic molecules such as acyclovir which are active against the herpes virus. (1)

ROCHESTER, NY, UNITED STATES, October 21, 2015 /EINPresswire.com/ --

“Infected with the herpes virus (HSV-1 or HSV-2)? The CBCD recommends taking [Gene-Eden-VIR](#) or [Novirin](#).” - Greg Bennett, CBCD

Researchers from the University Jean Monnet of Saint-Etienne in France can have developed a new vaginal ring, “which is capable of delivering multiple active antiviral molecules against various STIs (sexually transmitted infections) for a long duration.” (1) Two of those STIs are HIV and genital herpes (HSV-2). According to Dr. Meriam Memmi, the lead researcher, a hydrophilic compound was added to the silicone of the ring, which allows antiviral drugs to be released from their reservoirs. These rings are then capable of “releasing concentrations of drugs between 1.5 and 3.5 milligrams per day for acyclovir and 3 to 5 milligrams per day for tenofovir for as long as 50 days. These are equivalent to doses needed to prevent viral STIs such as HIV-1 infection, hepatitis B and genital herpes.” (1) This is important because the antiviral drugs need to be delivered to the body over a long period of time in order “to effectively neutralize viruses present in semen.” (1)



The Center for the Biology of Chronic Disease (CBCD) reminds the public that this new silicone vaginal ring has not been tested on humans. The researchers noted that the vaginal rings “are intended to be evaluated in clinical trials, with plans of producing them commercially at high rate and low cost. Their research was presented at the 55th Inter-Science Conference on Antimicrobial Agents and Chemotherapy.” (1) This is important to understand since developing an effective product with FDA approved drugs takes time. Until this vaginal ring is FDA approved, the CBCD

Eden-VIR, which are HSV-2 remedies backed by clinical studies.

Click to learn more about [herpes symptoms](#).

The formula of Gene-Eden-VIR and Novirin was tested by Hanan Polansky and Edan Itzkovitz from the Center for the Biology of Chronic Disease (CBCD) in two clinical studies that followed FDA guidelines. The studies showed that the Gene-Eden-VIR formula is effective against HSV-2 and other herpes viruses. The clinical studies were published in the peer reviewed, medical journal Pharmacology & Pharmacy, the first, in a special edition on Advances in Antiviral Drugs. Study authors wrote that, "individuals infected with the (HSV-2 and other viruses)...reported a safe decrease in their symptoms following treatment with Gene-Eden-VIR." (2) The study authors also wrote that, "We observed a statistically significant decrease in the severity, duration, and frequency of symptoms." (2)

Both products can be ordered online on the Novirin and Gene-Eden-VIR websites, here:

<http://www.gene-eden-vir.com>

and

<http://www.novirin.com>

Gene-Eden-VIR and Novirin are natural antiviral dietary supplements. Their formula contains five natural ingredients: Selenium, Camellia Sinesis Extract, Quercetin, Cinnamomum Extract, and Licorice Extract. The first ingredient is a trace element, and the other four are plant extracts. Each ingredient and its dose was chosen through a scientific approach. Scientists at polyDNA, the company that invented and patented the formula, scanned thousands of scientific and medical papers published in various medical and scientific journals, and identified the safest and most effective natural ingredients against latent viruses. To date, Gene-Eden-VIR and Novirin are the only natural antiviral products on the market with published clinical studies that support their claims.

Note: Novirin contains the same formula as Gene-Eden-VIR. The difference between the products is that Novirin contains higher quality, more expensive ingredients.

The multipurpose vaginal ring used in the South African study is not the first vaginal ring to be researched for use against the herpes virus. Collaborative research from the University of Utah and the reproductive health research organization CONRAD showed that a vaginal ring using the topical microbicide tenofovir could help prevent HSV-2 transmission for up to 90 days. Their results were presented in November 2013 at the 2013 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition in San Antonio, Texas. (See healthline.com, Published on November 12, 2013) (3)

What treatments are available for those infected with the herpes virus?

"Two types of antiviral treatments against HSV are available: topical and oral. The treatments include penciclovir, acyclovir, famciclovir, and valaciclovir. However, their effectiveness is limited. For instance, a meta-analysis of five placebo-controlled and two dose comparison studies evaluated the effect of aciclovir, famciclovir or valaciclovir on symptoms. The meta-analysis showed that oral antiviral therapy decreases the duration and the associated pain of an outbreak by merely one day." (2) In light of this evidence, the CBCD recommends that HSV infected individuals take Novirin or Gene-Eden-VIR.

Find us on Facebook here: <https://www.facebook.com/GeneEdenVIR>

Follow us Twitter on here: @HananPolansky

All orders of these products are completely confidential, and no information is shared or sold to any third party. Privacy is assured.

References:

(1) Tecson, K. "Silicone vaginal rings protect women against herpes and HIV" - International Business Times, Published September 22 2015.

(2) Polansky, H., Itzkovitz, E. Gene-Eden-VIR Is Antiviral: Results of a Post Marketing Clinical Study. Published on August 12, 2013. <http://www.scirp.org/journal/PaperInformation.aspx?PaperID=36101#.VH2qQNKUf90>

(3) healthline.com - Haskins, J. "First Intravaginal Ring to Protect Against Pregnancy, HIV, and Herpes." Published on November 12, 2013. <http://www.healthline.com/health-news/hiv-new-intravaginal-ring-protects-against-pregnancy-stis-111213>

Greg Bennett
CBCD
585-250-9999
email us here

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2015 IPD Group, Inc. All Right Reserved.



